CHICAGO, IL / ACCESSWIRE / August 15, 2023 / Cosmos Health Inc. ("Cosmos Health" or "the Company") (NASDAQ:COSM), a diversified,...
Company Hopes in 30 Days to Begin Making Its Drug Candidate Available to Help Patients and Address Public Health Crisis...
COPENHAGEN, Denmark, Aug. 15, 2023 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced it will report second quarter...
The Agreement with a leading full turnkey manufacturer further strengthens the Company's progression towards expected first in human clinical trials...
NEW YORK and LONDON, Aug. 15, 2023 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), a late-stage biotechnology company developing...
FORT WORTH, Texas, Aug. 15, 2023 (GLOBE NEWSWIRE) -- Carhartt Inc., one of America’s leading manufacturers of durable workwear and...
ACLR8-LR, a double-blind, randomized, placebo-controlled Phase IIB study to determine efficacy of the ARAKODA® regimen of tafenoquine in COVID-19 patients...
Announces next steps for clinical development plan in severe liver diseasesBOSTON, Aug. 15, 2023 (GLOBE NEWSWIRE) -- Galecto, Inc. (NASDAQ:...
Conference Call to be Held Today at 8:30 A.M. ETHOUSTON, Aug. 15, 2023 (GLOBE NEWSWIRE) -- Bio-Path Holdings, Inc., (NASDAQ:BPTH),...
NOT FOR DISTRIBUTION TO U.S. NEWS WIRE SERVICES OR DISSEMINATION IN THE UNITED STATES TORONTO, ON, Aug. 15, 2023 (GLOBE...
– Continued operational execution across pipeline towards multiple clinical and regulatory value-driving milestones expected in the second half of 2023...
ColoAlert® Revenue Increases 108% Year Over Year in the First Six Months of 2023 ColoFuture and eAArly Detect Studies on...
Mylight study met its primary efficacy endpoint and showed no clinically meaningful differences to reference afliberceptResults offer hope of new...
Greenville, South Carolina, Aug. 14, 2023 (GLOBE NEWSWIRE) -- ARCpoint Inc. (TSXV: ARC) (the “Company” or “ARCpoint”) a leading US-based...
VANCOUVER, British Columbia, Aug. 14, 2023 (GLOBE NEWSWIRE) -- Mydecine Innovations Group (OTC: MYCOF) (FSE: 0NFA) ("Mydecine" or the "Company"),...
Calgary, Alberta--(Newsfile Corp. - August 14, 2023) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0) is pleased to announce...
Renowned scientist will advise on the development of IMUNON’s FixPlas and IndiPlas modalities in immuno-oncology LAWRENCEVILLE, N.J., Aug. 14, 2023...
Earl Douglas General Counsel, Allogene TherapeuticsSOUTH SAN FRANCISCO, Calif., Aug. 14, 2023 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO),...
Announced today that all 3 patients (100% response rate) treated with ELX-02 showed an improvement in podocyte foot process effacement post-treatment...
Phase 1/2a SIGNAL-AD Study of Pepinemab in Alzheimer’s Disease Achieves Full Accrual Expect to Complete 12-months treatment in June, 2024...